{{orphan|time=2018-06-21T13:44:16+00:00}}
{{Translating|||time=2018-06-20T21:40:34+00:00}}
<!--TODO:
ref貌似有重复的（4/5）-->
{{医学声明}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470615044
| IUPAC_name = 1-(2,3,4-trimethoxybenzyl)piperazine
| image = Trimetazidine.svg

<!--Clinical data-->
| tradename =Vastarel  
| Drugs.com = {{drugs.com|international|trimetazidine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = CD
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| bioavailability = 约5小时后完全吸收，60小时后药物浓度趋于稳定
| protein_bound = 低（16%）
| metabolism = 极少
| elimination_half-life = 7至12小时
| excretion = 主要由肾脏原状排出。肾脏受损时[[药物暴露|药物暴露]]有增长，严重受损时（CrCl <30 ml/min）平均增加3倍

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 5011-34-7
| ATC_prefix = C01
| ATC_suffix = EB15
| PubChem = 21109
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 19853
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = N9A0A0R9S8
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 203266

<!--Chemical data-->
| C=14 | H=22 | N=2 | O=3 
| molecular_weight = 266.336 g/mol
| smiles = O(c1ccc(c(OC)c1OC)CN2CCNCC2)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UHWVSEOVJBQKBE-UHFFFAOYSA-N
}}
'''曲美他嗪'''（Trimetazidine）是一种治疗[[心绞痛|心绞痛]]的药物，已被冠以许多种商品名销售。<ref name=brands/>该药物是由法国{{tsl|en|Laboratoires Servier}}开发和销售的第一种[[细胞保护作用|细胞保护性]]抗缺血剂。它是一种抗缺血（抗心绞痛）代谢剂，通过抑制[[脂肪酸代谢|脂肪酸代谢]]来改善{{tsl|en|myocardial||心肌}}葡萄糖的利用，也称为脂肪酸氧化抑制剂。

== 医疗用途 ==

曲美他嗪通常被用于心绞痛的长期治疗，在一些国家（如[[法国|法国]]）还用于治疗[[耳鸣|耳鸣]]与[[头晕|头晕]]。[[欧洲药品管理局|欧洲药品管理局]]（EMA）于2012年完成了对曲美他嗪的益处和风险审查，并建议限制使用含曲美他嗪的药物，以作为一线抗心绞痛治疗不能控制或不耐受情况下的心绞痛附加治疗。<ref name = "EMA_press_release"/>

心绞痛患者的对照研究显示曲美他嗪增加了{{tsl|en|coronary flow reserve|冠脉血流储备}}，从而延缓与运动有关的缺血发作，限制了运动造成的[[血壓|血壓]]快速波动，并对[[心率|心率]]没有显著影响，显着降低了心绞痛发作的频率，并使因心绞痛而使用{{tsl|en|Glyceryl trinitrate (pharmacology)||硝酸盐}}显着减少。

在患有[[冠狀動脈疾病|冠狀動脈疾病]]的糖尿病患者中，它改善了[[心室|左心室功能]]。近期，人们发现曲美他嗪对不同病因造成的[[心脏衰竭|心脏衰竭]]都有效果。<ref name="pmid16949492">{{cite journal |vauthors=Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A | title = A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure | journal = J. Am. Coll. Cardiol. | volume = 48 | issue = 5 | pages = 992–8 |date=September 2006 | pmid = 16949492 | doi = 10.1016/j.jacc.2006.03.060  }}</ref><ref name="pmid18765391">{{cite journal |vauthors=Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J | title = Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy | journal = Circulation | volume = 118 | issue = 12 | pages = 1250–8 |date=September 2008 | pmid = 18765391 | doi = 10.1161/CIRCULATIONAHA.108.778019 }}</ref>

== 不良反应 ==

人们曾认为曲美他嗪是一种安全性高、耐受性好的药物<ref>Ciapponi A1, Pizarro R, Harrison J. Trimetazidine for stable angina.Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003614</ref>。 It interacts with [[monoamine_oxidase_inhibitor|monoamine oxidase inhibitor]]s.

There is scarce information about trimetazidine's effect on mortality, cardiovascular events or quality of life. Long term randomized controlled trials comparing trimetazidine against standard anti-anginal agents, using clinically important outcomes would be justifiable.<ref name="pmid16235330">{{cite journal |vauthors=Ciapponi A, Pizarro R, Harrison J | title = Trimetazidine for stable angina | journal = Cochrane Database Syst Rev | volume = | issue = 4 | pages = CD003614 | year = 2005 | pmid = 16235330 | doi = 10.1002/14651858.CD003614.pub2 | url = http://summaries.cochrane.org/CD003614/trimetazidine-for-stable-angina }}</ref> Recently, an international multicentre retrospective cohort study has indeed shown that in patients with heart failure of different etiologies, the addition of trimetazidine on conventional optimal therapy can improve mortality and morbidity.<ref>Fragasso G, Rosano G, Baek Hong S, Sisakian H, Di Napoli P, Alberti L, Calori G, Kang SM, Sahakyan A, Vitale C, Marazzi G, Margonato A, Belardinelli R. Effect of partial acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol. 2013;163:320-5.</ref>

EMA recommends that doctors should no longer prescribe trimetazidine for the treatment of patients with [[tinnitus|tinnitus]], [[眩暈_(醫學)|vertigo]] or disturbances in vision.<ref name = "EMA_press_release">{{cite web | url = http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/06/WC500129070.pdf | title = European Medicines Agency recommends restricting use of trimetazidine-containing medicines | format = pdf | work = Press release | date = 2012-06-12 | publisher = European Medicines Agency }}</ref> The recent EMA evaluation also revealed high potential for [[Parkinsonian|Parkinsonian]] (or extrapyramidal) symptoms (such as tremor, rigidity, akinesia, hypertonia), gait instability, [[restless_leg_syndrome|restless leg syndrome]], other related  movement disorders, reversible after treatment discontinuation. As a consequence, doctors are advised not to prescribe the medicine either to patients with Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome or other related movement disorders, nor to patients with severe renal impairment.<ref name = "EMA_press_release"/>

== 作用机制 ==

曲美他嗪阻碍长链[[HADHB|HADHB]]生成，从而抑制[[脂肪酸|脂肪酸]]的[[β-氧化|β-氧化]]并促进葡萄糖的氧化<ref name = "Kantor_2000">{{cite journal |vauthors=Kantor PF, Lucien A, Kozak R, Lopaschuk GD | title = The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase | journal = Circ. Res. | volume = 86 | issue = 5 | pages = 580–8 |date=March 2000 | pmid = 10720420 | doi = 10.1161/01.RES.86.5.580  }}</ref>。在缺血的细胞中，要得到同样多的能量，与脂肪酸β-氧化相比，葡萄糖氧化消耗的氧气更少。因此，曲美他嗪使细胞缺血时也能获取足够的能量，并维持其代谢。这样，缺氧或缺血细胞内的ATP浓度便不会下降，这保证了离子泵与跨膜钠-钾运输的正常运作，保持着细胞的动态平衡。<ref name = "Stanley_Marzilli_2003">{{cite journal |vauthors=Stanley WC, Marzilli M | title = Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine | journal = Fundam Clin Pharmacol | volume = 17 | issue = 2 | pages = 133–45 |date=April 2003 | pmid = 12667223 | doi = 10.1046/j.1472-8206.2003.00154.x }}</ref>

== 社会文化 ==
曲美他嗪是正在受到[[世界反運動禁藥機構|世界反運動禁藥機構]]测试的体能增强药物之一。

===商品名===
曲美他嗪已被冠以众多品牌名分销，包括：3 Kat、Adexor、Aiyiling、Angimax、Angimet、Anginox、Angintriz、Angiozil、Angirel、Angirid、Angitrim、Angivas、Angivent、Antoris、ApoTrimet、Apstar、Atanol、Bustidin、Cardimax、Carvidon、Curime、Cyto-Protectin、Cytogard、Dilatan、Dimesar、Domisin、Energotrim、Feelnor、Idaptan、Imovexil、Intervein、Invidon、Kardin、Liomagen、Matenol、Metacard、Metacardia、Metagard、Metazydyna、Mezitan、Miozidine、Moduxin、Neotri、Novazidine、Portora、Prectazidine、Predizin、Predozone、Preductal、Predutrim、Preduxl、Protevasc、Rimecor、Setal、Sitorel、Tacirel、Tazidinol、Tazz、TevaTrim、TMZ、Triacyt、Tricardia、Triguard、Trimductal、Trimecard、Trimeductan、Trimektal、Trimeluzine、Trimepect、Trimerel、Trimet、Trimetacor、Trimetaratio、Trimetazidin、Trimetazidinã、Trimetazidine、Trimetazidinum、Trimetazigen、Trimetazydyna、Trimezar、Trimpol、Trizedon、Trizid、Trizidine、Tryme、Vascotasin、Vascotazin、Vashasan、Vasorel、Vasotrim、Vaspycar、Vastar、Vastarel、Vastazid、Vastinan、Vastinol、Vastor、Vestar、Vosfarel、Whilst、Ze Wei Er、Zidimet、Zidin、Zidmetin、Zilutra、Zimetin等。<ref name=brands>{{cite web|title=Trimetazidine – International brands|url=https://www.drugs.com/international/trimetazidine.html|publisher=Drugs.com|accessdate=7 May 2017}}</ref>

== 参考文献 ==
{{Reflist}}

== 拓展阅读 ==
{{refbegin}}
* {{cite journal |vauthors=Sellier P, Broustet JP | title = Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study | journal = Am J Cardiovasc Drugs | volume = 3 | issue = 5 | pages = 361–9 | year = 2003 | pmid = 14728070 | doi = 10.2165/00129784-200303050-00007 }}
* {{cite journal |vauthors=Génissel P, Chodjania Y, Demolis JL, Ragueneau I, Jaillon P | title = Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers | journal = Eur J Drug Metab Pharmacokinet | volume = 29 | issue = 1 | pages = 61–8 | year = 2004 | pmid = 15151172 | doi = 10.1007/BF03190575 }}
{{refend}}

<!--{{Piperazines}}-->

[[Category:抗心绞痛药|Category:抗心绞痛药]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:芳香醚|Category:芳香醚]]
<!--[[Category:Laboratoires_Servier|Category:Laboratoires Servier]]-->
<!--[[Category:World_Anti-Doping_Agency_prohibited_substances|Category:World Anti-Doping Agency prohibited substances]]-->